{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:27:16Z","timestamp":1788881236056,"version":"build-2803163510"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:00:00Z","timestamp":1640908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse reaction in cancer patients treated with several cytotoxic anticancer agents including paclitaxel. Duloxetine, an antidepressant known as a serotonin-noradrenalin reuptake inhibitor, is the only agent that has moderate evidence for the use to treat painful CIPN. The present retrospective cohort study aimed to analyze risk factors for paclitaxel-induced peripheral neuropathy (PIPN), and investigate ongoing prescription drug use for PIPN in Japan. Female breast and gynecologic cancer patients who underwent paclitaxel-based chemotherapy at a single center in Japan between January 2016 and December 2019 were enrolled in this study. Patients\u2019 information obtained from electronic medical records were statistically analyzed to test possible risk factors on PIPN diagnosis. Patients\u2019 age, total paclitaxel dose, the history of female hormone-related diseases, hypertension and body mass index (BMI), but not additional platinum agents, were significantly associated with increased PIPN diagnosis. Drugs prescribed for PIPN included duloxetine, pregabalin, mecobalamin and Goshajinkigan, a polyherbal medicine, regardless of poor evidence for their effectiveness against CIPN, and were greatly different between breast and gynecologic cancer patients diagnosed with PIPN at the departments of Surgery and Gynecology, respectively. Thus, older age, greater total paclitaxel dose, the history of estrogen-related diseases, hypertension and BMI are considered risk factors for PIPN in paclitaxel-based chemotherapy of female cancer patients. It appears an urgent need to establish a guideline of evidence-based pharmacotherapy for PIPN.<\/jats:p>","DOI":"10.1371\/journal.pone.0261473","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T18:28:37Z","timestamp":1640975317000},"page":"e0261473","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan"],"prefix":"10.1371","volume":"16","author":[{"given":"Shiori","family":"Hiramoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Takegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3163-807X","authenticated-orcid":true,"given":"Atsufumi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,12,31]]},"reference":[{"issue":"8","key":"pone.0261473.ref001","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","volume":"22","author":"F Mols","year":"2014","journal-title":"Support Care Cancer"},{"issue":"4","key":"pone.0261473.ref002","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/COC.0b013e318246b50d","article-title":"Predicting acute and persistent neuropathy associated with oxaliplatin.","volume":"36","author":"LM Alejandro","year":"2013","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"pone.0261473.ref003","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00520-011-1336-0","article-title":"Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure","volume":"20","author":"CM Driessen","year":"2012","journal-title":"Support Care Cancer"},{"key":"pone.0261473.ref004","doi-asserted-by":"crossref","first-page":"102241","DOI":"10.1016\/j.ctrv.2021.102241","article-title":"Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN).","volume":"99","author":"DL Hertz","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"pone.0261473.ref005","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s43440-020-00109-y","article-title":"Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy","volume":"72","author":"K. Salat","year":"2020","journal-title":"Pharmacol Rep."},{"key":"pone.0261473.ref006","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2018.08.040","article-title":"Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk","volume":"141","author":"F Sekiguchi","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"pone.0261473.ref007","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12974-019-1581-6","article-title":"Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin\/thrombomodulin system in rodents: negative impact of anticoagulants.","volume":"16","author":"M Tsubota","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"1","key":"pone.0261473.ref008","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010367","article-title":"Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy.","volume":"22","author":"F Sekiguchi","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"pone.0261473.ref009","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3390\/cells10081881","article-title":"Macrophage as a peripheral pain regulator","volume":"10","author":"R Domoto","year":"2021","journal-title":"Cells"},{"issue":"24","key":"pone.0261473.ref010","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.2014.55.3073","article-title":"Breast and ovarian cancer in the older woman","volume":"32","author":"WP Tew","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"pone.0261473.ref011","first-page":"3014","article-title":"Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65","volume":"34","author":"DL Hershman","year":"2016","journal-title":"Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol"},{"issue":"4","key":"pone.0261473.ref012","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.","volume":"19","author":"Loibl S","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"pone.0261473.ref013","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.31798","article-title":"Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population","volume":"125","author":"MK Greenwald","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"pone.0261473.ref014","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000499599","article-title":"Prevention and Management of Chemotherapy-Induced Polyneuropathy.","volume":"14","author":"B Jordan","year":"2019","journal-title":"Breast Care (Basel)."},{"issue":"1","key":"pone.0261473.ref015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).","volume":"33","author":"WM Sikov","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0261473.ref016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jphs.2021.03.001","article-title":"Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study.","volume":"146","author":"T Miyamoto","year":"2021","journal-title":"J Pharmacol Sci"},{"issue":"28","key":"pone.0261473.ref017","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.","volume":"38","author":"CL Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"pone.0261473.ref018","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"EM Smith","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"pone.0261473.ref019","first-page":"359","article-title":"Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients","volume":"35","author":"A Otake","year":"2015","journal-title":"Anticancer Res"},{"issue":"5","key":"pone.0261473.ref020","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","article-title":"Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial.","volume":"20","author":"Y Hirayama","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"pone.0261473.ref021","doi-asserted-by":"crossref","first-page":"e000053","DOI":"10.1136\/esmoopen-2016-000053","article-title":"Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology.","volume":"1","author":"Y Hirayama","year":"2016","journal-title":"ESMO Open"},{"issue":"4","key":"pone.0261473.ref022","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00520-017-4028-6","article-title":"Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"26","author":"A Kuriyama","year":"2018","journal-title":"Support Care Cancer"},{"issue":"7","key":"pone.0261473.ref023","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00520-015-2725-6","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency.","volume":"23","author":"JM Schloss","year":"2015","journal-title":"Support Care Cancer"},{"issue":"1","key":"pone.0261473.ref024","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00520-016-3404-y","article-title":"A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).","volume":"25","author":"JM Schloss","year":"2017","journal-title":"Support Care Cancer"},{"issue":"8","key":"pone.0261473.ref025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082815","article-title":"Estrogen Receptors and Endometriosis.","volume":"21","author":"E Chantalat","year":"2020","journal-title":"Int J Mol Sci."},{"key":"pone.0261473.ref026","first-page":"6660087","article-title":"Molecular Targets and Associated Signaling Pathways of Jingshu Granules in Ovarian Cysts Based on Systemic Pharmacological Analysis","volume":"2021","author":"J Xu","year":"2021","journal-title":"Biomed Res Int"},{"issue":"2","key":"pone.0261473.ref027","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1933719115584449","article-title":"The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.","volume":"23","author":"Q Yang","year":"2016","journal-title":"Reprod Sci"},{"issue":"3","key":"pone.0261473.ref028","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2019EZR\u2019 for medical statistics","volume":"48","author":"Y. Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"pone.0261473.ref029","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","article-title":"Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer","volume":"11","author":"S Mielke","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"5","key":"pone.0261473.ref030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1634\/theoncologist.2018-0298","article-title":"Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101.","volume":"24","author":"M Barginear","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"pone.0261473.ref031","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1186\/s12885-018-4869-5","article-title":"Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer","volume":"18","author":"Z Ghoreishi","year":"2018","journal-title":"BMC Cancer"},{"key":"pone.0261473.ref032","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3389\/fncel.2018.00495","article-title":"Fractalkine\/CX3CR1 Contributes to Endometriosis-Induced Neuropathic Pain and Mechanical Hypersensitivity in Rats.","volume":"12","author":"Z Liu","year":"2018","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"pone.0261473.ref033","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/j.pain.0000000000001832","article-title":"Nonsurgical mouse model of endometriosis-associated pain that responds to clinically active drugs","volume":"161","author":"V Fattori","year":"2020","journal-title":"Pain"},{"issue":"19","key":"pone.0261473.ref034","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1158\/1078-0432.CCR-16-3224","article-title":"Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer","volume":"23","author":"ME Dolan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"pone.0261473.ref035","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00280-013-2306-7","article-title":"Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, doubleblind, placebocontrolled trial of goshajinkigan to prevent oxaliplatininduced neuropathy.","volume":"72","author":"T Kono","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"pone.0261473.ref036","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10147-017-1229-4","article-title":"Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.","volume":"23","author":"N Hoshino","year":"2018","journal-title":"Int J Clin Oncol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0307865","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T18:28:51Z","timestamp":1640975331000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261473"}},"subtitle":[],"editor":[{"given":"Nial J.","family":"Wheate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,31]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261473","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0307865","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,31]]}}}